Kenya Secures $2 Million Global Fund Grant to Launch Long-Acting HIV Prevention Injections

Kenya has reached a significant milestone in its public health strategy with the receipt of a Sh256 million ($2 million) grant from the Global Fund to support the rollout of Lenacapavir, a groundbreaking long-acting HIV prevention injection. The initiative was officially launched at the Riruta Health Centre in Nairobi, following the procurement of an initial 21,000 doses valued at Sh370 million ($2.9 million). This move marks a pivotal shift in the country's approach to HIV prevention, offering a more sustainable alternative for those who may find it challenging to adhere to daily oral medication schedules.

Lenacapavir, administered as a biannual injectable pre-exposure prophylaxis (PrEP), is designed to provide long-lasting protection with only two doses per year. The phased implementation of this program will prioritize high-risk populations across 15 selected counties identified as having a high burden of infection. Global Fund senior portfolio manager Paul Maccarrick emphasized the historic nature of the rollout, noting that it reflects a robust global partnership involving the Global Fund, PEPFAR, and Gilead Sciences. The ultimate objective is to drastically reduce new HIV transmissions, aligning with the national goal of achieving zero new infections by 2030.

The clinical administration of the drug has already commenced, with 27-year-old Samson Mutua becoming the first recipient in Kenya after following strict medical protocols. Health Cabinet Secretary Aden Duale confirmed the drug's safety and efficacy, reassuring the public of its rigorous testing. According to the Ministry of Health, beneficiaries must meet specific criteria to qualify for the injection, including a confirmed HIV-negative status and a body weight of at least 35 kg. These safeguards ensure that the long-acting PrEP is distributed effectively to those who will benefit most.

This initiative represents a major advancement in Kenya's healthcare landscape, potentially transforming HIV prevention for thousands of citizens. By integrating advanced medical technology with international financial support, the Kenyan government aims to overcome the barriers of traditional PrEP methods. As the rollout expands beyond the initial 15 counties, health officials expect the program to serve as a model for other nations in the region striving to eliminate HIV as a public health threat through innovation and strategic collaboration.